

IFW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
0VKH-103711

In Re Application Of: **Debasis Bagchi et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/805,129	3/19/2004	Not yet assigned	30764	1614	8914

Title: **METHOD AND COMPOSITION FOR DECREASING GHRELIN LEVELS**



Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
0VKH-103711

In Re Application: **Debasis Bagchi et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/805,129	3/19/2004	Not yet assigned	30764	1614	8914

Title: **METHOD AND COMPOSITION FOR DECREASING GHRELIN LEVELS**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-1853** as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

***This certificate may only be used if paying by deposit account.**

Signature

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" August 17, 2004

(Date)

Signature of Person Mailing Correspondence

Steve P. Hassid

Typed or Printed Name of Person Mailing Certificate

Dated: **August 17, 2004**

Steve P. Hassid, Esquire
Registration No. 46,762
Sheppard, Mullin, Richter & Hampton LLP
333 South Hope Street, 48th Floor
Los Angeles, California 90071-1448
(213) 620-1780

CC:

INFORMATION DISCLOSURE CITATION <small>(Use several sheets if necessary)</small>				ATTY DOCKET NO. 0YKH-103711		APPLICATION NO. 10/805,129	
				APPLICANT(S) Debasis Bagchi et al.			
				FILING DATE 3/19/2004		GROUP ART UNIT 1614	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	5,536,516	7/16/1996	Moffett et al.	426	271		
	5,656,314	8/12/1997	Moffett et al.	426	271		
	US 6,441,041 B1	8/27/2002	Clouatre et al.	514	574		
	US 6,447,807 B1	9/10/2002	Clouatre et al.	424	494		
	US 6,476,071 B1	11/5/2002	Clouatre et al.	514	557		

U.S. PATENT APPLICATION PUBLICATIONS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	US 2001/0044469 A1	11/22/2001	Clouatre et al.	514	575		
	US 2003/0133992 A1	7/17/2003	Bagchi et al.	424	643		
	US 2004/0014692 A1	1/22/2004	Bagchi et al.	514	33		

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
			Chromium Occurrence and Function in Biological Systems, by Walter Mertz, Physiological Reviews (1969)
			Influence of (-)-hydroxycitrate on lipogenesis in chickens and rats, by H. Chee, D.R. Romsos and G.A. Leville, www.ncbi.nlm.nih.gov (1977)

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY DOCKET NO. 0VKH-103711		APPLICATION NO. 10/805,129	
				Debasis Bagchi et al.			
				FILING 3/19/2004		GROUP ART 1614	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		US 6,482,858 B1	11/19/2002	Clouatre et al	514	574	

U.S. PATENT APPLICATION PUBLICATIONS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE


FOREIGN PATENT DOCUMENTS								
*	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>			
	*	EXAMINER INITIAL	Role of fatty acid synthesis in the control of insulin-stimulated glucose utilization by rat adipocytes by Susan K. Fried, Marcelle Lavau and F. Xavier Pi-Sunyer, Journal of Lipid Research, Volume 22 (1981)
			Implication of Steroid Saponins and Sapogenins in the Hypocholesterolemic Effect of Fenugreek by Yves Sauvaire, Gerald Ribes, Jean-Claude Baccou and Marie-Madeleine Loubalieires-Mariani, Lipids Volume 26 (1991)

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) 0VKH-103711		Application Number 10/805,129	
		Applicant(s) Debasis Bagchi et al.			
		Filing Date 3/19/2004		Group Art Unit 1614	
*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>				
	Antidiabetic effects of S-allyl cysteine sulphoxide isolated from garlic by C.G. Sheda & K.T. Augusti, Indian Journal of Experimental Biology Volume 30 (1992)				
	More direct evidence for a malonyl-CoA-carnitine palmitoyltransferase I interaction as a key event in pancreatic beta-cell signaling by S. Chen, A. Ogawa, M. Ohneda, R.H. Unger, D.W. Foster and J.D. McGarry, http://diabetes.diabetesjournals.org (1994)				
	More direct evidence for a malonyl-CoA-carnitine palmitoyltransferase I interaction as a key event in pancreatic beta-cell signaling, by S. Chen, A. Ogawa, M. Ohneda, R.H. Unger, D.W. Foster, J.D. McGarry, http://www.ncbi.nlm.nih.gov (1994)				
	Effects of chromium and guar on sugar-induced hypertension in rats, by H.G. Preuss, J.A. Gondal, E. Bustos, N. Bushehri, S. Lieberman, N.A. Brayden, M.M. Polansky and R.A. Anderson, Clinical Nephrology, Volume 44, No. 3 (1995)				
	New Information on (-)-Hydroxycitric Acid/HCA, by Dallas Cloutre, Ph.D., Cloutre Consulting Group (1995)				
	Current Zinc Intake and Risk of Diabetes and Coronary Artery Disease and Factors Associated with Insulin Resistance in Rural and Urban Populations of North India, by Ram B. Singh, M.D., Mohammad A. Niaz, PhD, Shanti S. Rastogo, M.D., Sarita Bajaj, Zhang Gaoli and Zhu Shoumin, PhD, Journal of the American College of Nutrition Volume 17, No. 6 (1998)				
	Toward a Wholly Nutritional Therapy for Type 2 Diabetes by M.F. McCarty, http://www.sciencedirect.com (2000)				
	Clinical Study on Ephedra-Free Super Citrimax Published in Nutrition Research (2004)				
	Researchers Reveal the Beauty of Super CitriMax - Again, Inter Health (2004)				
	The Diet and Health Benefits of HCA (Hydroxycitric Acid) How This All-Natural Diet Aid Promotes Weight Loss and Inhibits Fat Production, by Dallas Cloutre, Ph.D. and Michael Rosenbaum, M.D., A Good Health Guide (undated)				
EXAMINER		DATE CONSIDERED			
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>					



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/805,129
Applicants: Debasis Bagchi et al.
Filed: March 19, 2004
Title: METHOD AND COMPOSITION FOR
DECREASING GHRELIN LEVELS
Group Art Unit: 1614
Examiner: Not yet assigned
Docket No.: 0VKH-103711
Date: August 17, 2004

Commissioner for Patents
Post Office Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants submit the enclosed copies of references that might be deemed material to the examination of the above-identified application. The documents are identified on the attached form PTO-A820, "Information Disclosure Citation."

Applicants respectfully request that the identified document be considered in the examination of this application, and that its consideration be made of written record in the application file.

Respectfully submitted,

SHEPPARD, MULLIN, RICHTER & HAMPTON LLP

By: 

Steve P. Hassid
Registration No. 46,762

333 South Hope Street, 48th Floor
Los Angeles, California 90071
(213) 617-1780